Related Experiment Video
Updated: Nov 29, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Preclinical pharmacokinetic study of a novel lipid-lowering agent, IMM-H007
Abstract:
The article "Preclinical pharmacokinetic study of a novel lipid-lowering agent, IMM-H007, by Z.-L. Zhang, W.-Q. Liu, X.-Z. Deng, published in Eur Rev Med Pharmacol Sci 2018; 22 (24): 8939-8950-DOI: 10.26355/eurrev_201812_16664-PMID: 30575938" has been withdrawn from the authors stating that "after our article was published, we received a conflict of interest from the Chinese Academy of Sciences. They declared that they developed IMM-H007 for the first time and they had already applied for the patent. We had already cited in the references that IMM-H007 came from the Chinese Academy of Sciences. But they still insisted that we had violated their rights. We had to withdraw our paper in order to avoid greater conflicts and disputes". The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/16664.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Study Design: Healthy Subjects Versus Patients
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

